Darusentan Data to Be Presented at AHA 2006 -- Chicago
November 06 2006 - 8:00AM
Business Wire
Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on
the discovery, development and commercialization of small molecule
therapeutics for the treatment of cardiovascular disorders, today
announced that an abstract describing the effects of darusentan on
resistant hypertension has been selected for oral presentation at
the American Heart Association Scientific Sessions conference to be
held Nov. 12-15, 2006, at the McCormick Place Convention Center in
Chicago, Ill. Michael Weber, M.D., will present �Darusentan
Significantly Reduces Systolic Blood Pressure in Patients with
Resistant Hypertension on Four or More Antihypertensive Drugs.� The
presentation is scheduled for Monday, Nov. 13, 2006, from 2:15 p.m.
to 2:30 p.m. Dr. Weber is an Associate Dean and Professor of
Medicine at the State University of New York Health Science Center
in Brooklyn, N.Y., and is a member of the clinical advisory group
for the darusentan development program. Myogen has two product
candidates in late-stage clinical development: ambrisentan for the
treatment of patients with pulmonary arterial hypertension (PAH)
and darusentan for the treatment of patients with resistant
hypertension. Myogen and GlaxoSmithKline have entered into a global
PAH collaboration in which Myogen has marketing and distribution
rights to GlaxoSmithKline's Flolan� (epoprostenol sodium) for
injection in the United States and GlaxoSmithKline has licensed
ambrisentan from Myogen for all territories outside of the United
States, where Myogen retains exclusive rights. Myogen also conducts
a target and drug discovery research program focused on the
development of disease-modifying drugs for the treatment of chronic
heart failure and related cardiovascular disorders. Please visit
Myogen's website at www.myogen.com. Safe Harbor Statement The
anticipated presentation will contain forward-looking statements
that involve significant risks and uncertainties, including those
to be discussed in the presentation and others that can be found in
the �Risk Factors� section of Myogen�s Form 10-K for the year ended
December 31, 2005 and Myogen�s periodic reports on Form 10-Q and
Form 8-K. Results from clinical trials, including the Company's
Darusentan Phase 2b trial, are not necessarily predictive of future
clinical results. Myogen does not undertake any obligation to
update any forward-looking statements contained in the anticipated
presentation as a result of new information, future events or
otherwise. The company cautions investors not to place undue
reliance on the forward-looking statements contained in this press
release or the presentation. No forward-looking statement can be
guaranteed and actual events and results may differ materially from
those projected. Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical
company focused on the discovery, development and commercialization
of small molecule therapeutics for the treatment of cardiovascular
disorders, today announced that an abstract describing the effects
of darusentan on resistant hypertension has been selected for oral
presentation at the American Heart Association Scientific Sessions
conference to be held Nov. 12-15, 2006, at the McCormick Place
Convention Center in Chicago, Ill. Michael Weber, M.D., will
present "Darusentan Significantly Reduces Systolic Blood Pressure
in Patients with Resistant Hypertension on Four or More
Antihypertensive Drugs." The presentation is scheduled for Monday,
Nov. 13, 2006, from 2:15 p.m. to 2:30 p.m. Dr. Weber is an
Associate Dean and Professor of Medicine at the State University of
New York Health Science Center in Brooklyn, N.Y., and is a member
of the clinical advisory group for the darusentan development
program. Myogen has two product candidates in late-stage clinical
development: ambrisentan for the treatment of patients with
pulmonary arterial hypertension (PAH) and darusentan for the
treatment of patients with resistant hypertension. Myogen and
GlaxoSmithKline have entered into a global PAH collaboration in
which Myogen has marketing and distribution rights to
GlaxoSmithKline's Flolan(R) (epoprostenol sodium) for injection in
the United States and GlaxoSmithKline has licensed ambrisentan from
Myogen for all territories outside of the United States, where
Myogen retains exclusive rights. Myogen also conducts a target and
drug discovery research program focused on the development of
disease-modifying drugs for the treatment of chronic heart failure
and related cardiovascular disorders. Please visit Myogen's website
at www.myogen.com. Safe Harbor Statement The anticipated
presentation will contain forward-looking statements that involve
significant risks and uncertainties, including those to be
discussed in the presentation and others that can be found in the
"Risk Factors" section of Myogen's Form 10-K for the year ended
December 31, 2005 and Myogen's periodic reports on Form 10-Q and
Form 8-K. Results from clinical trials, including the Company's
Darusentan Phase 2b trial, are not necessarily predictive of future
clinical results. Myogen does not undertake any obligation to
update any forward-looking statements contained in the anticipated
presentation as a result of new information, future events or
otherwise. The company cautions investors not to place undue
reliance on the forward-looking statements contained in this press
release or the presentation. No forward-looking statement can be
guaranteed and actual events and results may differ materially from
those projected.
Myogen (NASDAQ:MYOG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myogen (NASDAQ:MYOG)
Historical Stock Chart
From Sep 2023 to Sep 2024